Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 9INDUSTRY 5NIH 3

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Thoracic 3Genitourinary 1

Conditions

Melanoma 1103Carcinoma, Non-Small-Cell Lung 281Neoplasms 199Keratosis, Actinic 181Carcinoma, Renal Cell 162Skin Neoplasms 143Colorectal Neoplasms 142Neoplasm Metastasis 140Squamous Cell Carcinoma of Head and Neck 134Breast Neoplasms 118Ovarian Neoplasms 114Carcinoma, Basal Cell 97Stomach Neoplasms 94Pancreatic Neoplasms 93Lung Neoplasms 91Head and Neck Neoplasms 90Lymphoma, T-Cell, Cutaneous 88Uterine Cervical Neoplasms 75Triple Negative Breast Neoplasms 74Sarcoma 68Carcinoma, Hepatocellular 67Prostatic Neoplasms 65Uveal Melanoma 64Carcinoma, Merkel Cell 64Urinary Bladder Neoplasms 63Esophageal Neoplasms 61Carcinoma, Transitional Cell 57Lymphoma 55Endometrial Neoplasms 55Small Cell Lung Carcinoma 52

Interventions

pembrolizumab 3relatlimab 1lifileucel 1dabrafenib 1Temozolomide 1Paclitaxel 1Opdualag 1Nivolumab 1Ipilimumab 1Dacarbazine 1Carboplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Melanoma, Cutaneous Malignant × Dermatologic × Clear all
NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting
360 enrolled
Dermatologic

Melanoma, Cutaneous Malignant

NCT05479812 2026-02-09

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

Werewolf Therapeutics, Inc.

Phase 1 Active not recruiting
150 enrolled
DermatologicGenitourinaryThoracic

Melanoma, Cutaneous Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT05585320 2025-09-02

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

Immuneering Corporation

Phase 1/2 Active not recruiting
209 enrolled
DermatologicThoracic

Melanoma, Cutaneous Malignant, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06208124 2025-05-28

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

Immuneering Corporation

Phase 1/2 Completed
30 enrolled
DermatologicThoracic

Melanoma, Cutaneous Malignant, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT03541148 2018-05-30

Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma

Catalysis SL

Phase 2 Completed
20 enrolled
Dermatologic

Melanoma, Cutaneous Malignant, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡